Thalassemia Diagnostic Market to be Dominated by Hospitals & Clinics segment through 2028
Advancements in diagnostic technologies and growing awareness
about thalassemia is expected to drive the global thalassemia diagnostic market
in the forecast period 2024-2028
According to the TechSci Research
report, “Thalassemia Diagnostic
Market - Global Industry Size, Share, Trends, Opportunity, and Forecast,
2018-2028”, Global Thalassemia Diagnostic market is anticipated
to upsurge at an impressive rate in the forecast period of 2028. Individuals with thalassemia
produce fewer healthy red blood cells and are therefore at a higher risk of
developing anemia, fatigue, and other complications. The disorder is
particularly prevalent in countries around the Mediterranean, Middle East, and
Asia, where the gene mutations are more common. The, supportive government
policies in these countries have played a significant role in influencing the
demand for the global thalassemia diagnostic market. Governments have invested
in research and development, provided funding to increase access to diagnostic
tests, implemented policies for mandatory screening, and launched awareness
campaigns to increase understanding about the disorder. These efforts have led
to an increase in the demand for thalassemia diagnostic tests and have helped
to improve the quality of care for individuals with thalassemia. Apart from
these, the growing awareness about thalassemia has led to an increase in the
demand for thalassemia diagnostic tests. Diagnostic tests for thalassemia
include blood tests, DNA analysis, and hemoglobin electrophoresis. These tests
are used to screen, diagnose, and monitor the disease. As more people seek
diagnostic tests for thalassemia, the demand for thalassemia diagnostic tests
is expected to continue to grow.
While advancements in diagnostic
technologies have greatly improved the detection and management of thalassemia,
there are still challenges that need to be addressed such as cost of diagnostic
tests, access to diagnostic tests, accuracy of diagnostic tests, interpretation
of test results, and standardization of diagnostic tests. In many parts of the
world, access to diagnostic tests for thalassemia is limited. This can result
in delayed or inaccurate diagnosis, and a lack of proper management and
treatment for affected individuals, thereby hampering the growth of global
thalassemia diagnostics market. At the same time, some of the advanced diagnostic technologies
used for thalassemia, such as genetic testing, can be expensive. This can be a
barrier to accessing these tests, particularly in low-income areas or
countries. Therefore, all the above factor is expected to impend the growth of thalassemia
diagnostic market.
Browse over XX market data
Figures spread through XX Pages and an in-depth TOC on the "Thalassemia Diagnostic Market"
Global thalassemia diagnostic market is
segmented based on type, end-user, and region.
Based on type, the global thalassemia
diagnostic market is segmented into complete blood cell (CBC) tests, hemoglobin
tests, iron deficiency tests, DNA tests, and others. The complete blood cell (CBC)
tests segment is
expected to hold the largest market share in the forecast period owing to widely
available, affordable and reliable. CBC tests can measure the number and size
of red blood cells, which are affected by thalassemia. CBC tests can also
detect other blood disorders that may coexist with thalassemia, such as anemia
or iron deficiency.
Based
on end-user, the global thalassemia
diagnostic market is fragmented into hospitals
& clinics, diagnostic laboratories, and others. The hospitals & clinics segment is
expected to hold the highest market share in the segment as hospitals &
clinics have more access to advanced diagnostic technologies and skilled
professionals. They also serve a large number of patients with thalassemia who
need regular blood transfusions and monitoring.
Major companies operating in the global thalassemia
diagnostic market are:
- Hybribio Limited
- Oasis Diagnostics Corporation
- ViennaLab Diagnostics GmbH
- GENETEK BIOPHARMA GmbH
- Devyser Diagnostics AB
- Yaneng BIOscience (Shenzhen) Co., Ltd.
- BioLab Diagnostics India Private Limited
- NPT Co. Ltd.
- Bio-Rad Laboratories, Inc.
Download Free Sample Report
Customers can also request for 10% free
customization on this report.
“Global thalassemia
diagnostics market is experiencing growth due to several factors, including
increasing prevalence of thalassemia, rising awareness and screening programs,
and supportive government policies. Thalassemia is a genetic blood disorder
that affects the production of hemoglobin and can lead to anemia, organ damage,
and other serious complications. As awareness of the disorder increases, more
individuals are being screened for thalassemia, leading to an increased demand
for diagnostic tests. Furthermore, advancements in diagnostic technologies have
also contributed to the growth of the thalassemia diagnostics market. Genetic
testing, point-of-care testing, molecular and cellular technologies, imaging
technologies, and liquid biopsy are among the most significant advancements
that have improved the sensitivity and accuracy of diagnostic tests for
thalassemia. These technologies have also enabled early detection and
monitoring of the disorder, which is crucial for proper management and
treatment of Top of Formthalassemia
are likely to benefit from the market growth and create huge prospects of thalassemia
diagnostic market growth during the forecast period,” said Mr. Karan Chechi,
Research Director with TechSci Research, a research-based global management
consulting firm.
“Thalassemia Diagnostic Market - Global
Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented
By Type (Complete Blood Cell (CBC) Test, Hemoglobin Test, Iron Deficiency Test,
DNA Tests, Others), By End User
(Hospitals & Clinics, Diagnostic Laboratories, Others), By Region, and
Competition, has evaluated the future
growth potential of global thalassemia diagnostic market and provides
statistics & information on market size, structure, and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in the global thalassemia diagnostic market.”
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com